Interleukin-4 receptor signaling and its binding mechanism: A therapeutic insight from inhibitors tool box

Z Ul-Haq, S Naz, MA Mesaik - Cytokine & growth factor reviews, 2016 - Elsevier
Abstract Studies on Interlukin-4 (IL-4) disclosed great deal of information about its various
physiological and pathological roles. All these roles depend upon its interaction and …

Understanding the immunodeficiency in chronic lymphocytic leukemia: potential clinical implications

JC Riches, JG Gribben - Hematology/Oncology Clinics, 2013 - hemonc.theclinics.com
Chronic lymphocytic leukemia (CLL) is the most common leukemia in adults, with a lifetime
risk of 0.49%. 1 It is characterized by the clonal expansion of CD5+ IgD+/IgM+ B …

The circulating dendritic cell compartment in patients with chronic lymphocytic leukemia is severely defective and unable to stimulate an effective T-cell response

E Orsini, A Guarini, S Chiaretti, FR Mauro, R Foa - Cancer research, 2003 - AACR
Chronic lymphocytic leukemia (CLL), the most frequent leukemia in the Western world, is
characterized by a profound dysregulation of the host immune system that has a marked …

Microenvironment dependency in Chronic Lymphocytic Leukemia: The basis for new targeted therapies

E Ten Hacken, JA Burger - Pharmacology & therapeutics, 2014 - Elsevier
Abstract Chronic Lymphocytic Leukemia (CLL) is a prototype microenvironment-dependent
B-cell malignancy, in which the neoplastic B cells co-evolve together with a supportive tissue …

Soluble CD200 is critical to engraft chronic lymphocytic leukemia cells in immunocompromised mice

KK Wong, F Brenneman, A Chesney, DE Spaner… - Cancer research, 2012 - AACR
CD200 is a transmembrane molecule with an important immunoregulatory role that is
overexpressed on most chronic lymphocytic leukemia (CLL) cells. In this study, we …

T-cell function in chronic lymphocytic leukaemia

JC Riches, AG Ramsay, JG Gribben - Seminars in cancer biology, 2010 - Elsevier
According to the immune-surveillance hypothesis, cancer cells evolve strategies to evade or
suppress the immune system as part of the development of this disease. The malignant B …

CAR therapy for hematological cancers: can success seen in the treatment of B-cell acute lymphoblastic leukemia be applied to other hematological malignancies?

HJ Pegram, EL Smith, S Rafiq, RJ Brentjens - Immunotherapy, 2015 - Taylor & Francis
Chimeric antigen receptor (CAR) T-cell therapy has recently come into the spotlight due to
impressive results in patients with B-cell acute lymphoblastic leukemia. By targeting CD19, a …

Lysophosphatidic acid (LPA) protects primary chronic lymphocytic leukemia cells from apoptosis through LPA receptor activation of the anti-apoptotic protein AKT/PKB

X Hu, N Haney, D Kropp, AF Kabore… - Journal of Biological …, 2005 - ASBMB
Lysophosphatidic acid (LPA) protects epithelial and fibroblast cell lines from apoptosis. In B-
cells, LPA acts as a growth factor promoting cell proliferation. Chronic lymphocytic leukemia …

Interleukin‐1B (IL1B) and interleukin‐6 (IL6) gene polymorphisms are associated with risk of chronic lymphocytic leukaemia

MG Ennas, PS Moore, M Zucca… - Hematological …, 2008 - Wiley Online Library
Common polymorphisms in genes encoding for cytokines implicated in the inflammatory
response and Th1/Th2 balance might play a role in the development and prognosis of …

IL-4 biology: impact on normal and leukemic CLL B cells

NE Kay, BT Pittner - Leukemia & lymphoma, 2003 - Taylor & Francis
This review provides a perspective on the role of IL-4 in relation to both normal and leukemic
CLL B cells. IL-4 is a well-characterized cytokine known to be produced by normal T cells …